Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andamertinib - Avistone Pharmaceuticals

Next Previous
Drug Profile

Andamertinib - Avistone Pharmaceuticals

Alternative Names: Andatinib - Avistone Pharmaceuticals; PLB-1004

Latest Information Update: 20 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avistone Pharmaceuticals
  • Class Aniline compounds; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 14 Jan 2026 Avistone Biotechnology plans the phase II KANNON-5 trial for Non-small cell lung cancer (Inoperable/unresectable, First-line therapy, Late-stage disease, Metastatic disease, Monotherapy) (PO, Capsule) in January 2026 (NCT07336732)
  • 16 Dec 2025 Avistone Pharmaceuticals in collaboration with Beijing Pearl Biotechnology plans a phase Ib/II trial for Non-small cell lung cancer (Second-line therapy or greater, First line therapy, Combination therapy, Metastatic disease, Late-stage disease, Inoperable/Unresectable) in (USA) (PO, Tablet) in June 2026 (NCT07285148)
  • 31 Jul 2025 Avistone Pharmaceuticals plans a phase Ib/II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in China (PO), in August 2025 (NCT07063329)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top